CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Metastatic Castration-Resistant Prostate Cancer
Oncology Nursing News
Precision Medicine in Oncology
Soft Tissue Sarcoma
Special Reports in Personalized Cancer Care
Online Continuing Education Activities
SELECT A TOPIC
<< View More Conferences
2017 SGO Annual Meeting
Oncology Conference Multimedia
View more videos >>
Dr. Annunziata on Olaparib and Cediranib Combination in Ovarian Cancer
Dr. Altman on Neoadjuvant Chemotherapy in High-Grade Serous Carcinoma
Dr. Brown on Genetic Counseling for Breast and Ovarian Cancer
Oncology Conference Articles
Immunotherapy AXAL Tops Survival Mark in Cervical Cancer
An immunotherapy targeting HPV-infected cells led to an unprecedented 1-year survival rate in patients with recurrent, metastatic cervical cancer.
Maintenance Chemotherapy Yields No OS Benefit in Ovarian Cancer
Maintenance chemotherapy after debulking surgery and adjuvant platinum-based chemotherapy did not improve overall survival rates in women with ovarian cancer who had achieved complete remission.
Maintenance Olaparib Shows Impressive PFS Benefit for BRCA+ Ovarian Cancer
Maintenance therapy with olaparib showed a 70% reduction in the risk of progression or death compared with placebo for patients with platinum-sensitive, relapsed
-mutant ovarian cancer.
Carboplatin Hypersensitivity Linked to BRCA Deficiency in Ovarian Cancer
Treatment with a carboplatin desensitization regimen led to improved overall survival in patients with
-proficient ovarian cancer.
MMR Deficiency Linked to PD-L1 Expression in Endometrial Cancer
Mismatch repair-deficient endometrial cancers exhibited significantly higher levels of PD-L1 expression compared with MMR-intact tumors.
Niraparib Effective in Ovarian Cancer, Regardless of BRCA Status
The PARP inhibitor niraparib improved progression-free survival in patients with recurrent, platinum-sensitive, high-grade ovarian cancer, regardless of
status, according to a review of the phase III ENGOT-OV16/NOVA trial presented at the 2017 Society of Gynecologic Oncology Annual Meeting.
Parents Continue to See HPV Vaccine as Unnecessary and Worry Over Its Safety
A survey was given to parents of teenage girls in an effort to understand the relatively low uptake of the HPV vaccine in the United States.
Tumor Gene Methylation May Predict Ovarian Cancer Response to Rucaparib
Hypermethylation of 2 wild-type tumor-associated genes increased ovarian cancer responsiveness to the PARP inhibitor rucaparib (Rubraca).
Gynecologic Oncologists Cite Time, Money as Barriers to Global Health Participation
Lack of clinical coverage and time off topped the perceived hindrances to gynecologic oncologists’ participation in global health activities, according to a study reported at the Society of Gynecologic Oncology in National Harbor, MD.
New Insights Into Rucaparib Activity in Ovarian Cancer
The PARP inhibitor rucaparib slowed progression of relapsed
-mutant ovarian cancer regardless of whether the mutations were somatic or germline, a new analysis of a phase II trial showed.
NDA Withdrawn in Melanoma, Promising Phase III Results in Breast Cancer and Ovarian Cancer, and More
FDA Approves Niraparib for Ovarian Cancer
Expert Discusses QoL Benefits of Active Surveillance for Low-Risk Prostate Cancer
Efforts Continue to Introduce Immunotherapy Into Earlier NSCLC Settings
Expert Tackles Efficacy of PD-L1 Testing for NSCLC in 2017
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2017
Intellisphere, LLC. All Rights Reserved.